Clinical trial

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients…

NCT00332891 · Sanofi, Industry · Completed

Key facts

NCT number NCT00332891
Title An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
Official title An 8-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Paroxetine (20 mg q24) as Positive Control, Evaluating the Efficacy and Safety of 2 Fixed Doses of SR58611A (175 mg q12 and 350 mg q12) in Outpatients With GAD
Acronym ELECTRA
Lead sponsor Sanofi, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Anxiety Disorders
Intervention type Drug
Interventions SR58611A
Enrollment 508
Start date Mar 1, 2006
Primary completion Apr 1, 2007
Completion Apr 1, 2007
First posted Jun 2, 2006
Last update posted Mar 9, 2009
Countries Bulgaria, Croatia, Czechia, Poland, Serbia

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies